AVEO Oncology (NSDQ:AVEO) announced today that it entered into a clinical trial collaboration with Bristol Myers Squibb. Boston-based AVEO’s collaboration and supply agreement with Bristol Myers Squibb is slated to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab), an anti-PD-1 therapy developed by Bristol Myers Squibb. The drugs will be evaluated in a pivotal Phase […]
Injectable medicine technology developer ApiJect Systems appoints new COO
ApiJect Systems announced that Raymond J. Guidotti joined the company as its new chief operating officer. Stamford, Conn.-based ApiJect, which develops technologies for vaccines and injectable medicines to be filled, finished and delivered, made the personnel move effective on March 1, 2021, according to a news release. Guidotti is a veteran of more than 30 […]
Ocular Therapeutix reports Q4 misses
Ocular Therapeutix (NSDQ:OCUL) reported fourth-quarter results that missed the consensus forecast. The Bedford, Mass.–based eye disease therapeutic developer posted losses of –$85.6 million, or –$1.21 per share, on sales of $7.3 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of –$26 million last year despite more than […]
Savara prices $113M offering
Savara (NSDQ:SVRA) announced today that it priced an underwritten public offering of common stock at approximately $113 million. Austin, Texas-based Savara — an orphan lung disease treatment company with an inhaled formulation of recombinant human GM-CSF — is offering nearly 45.8 million shares of its common stock to the public for $1.45 per share, according to […]
AFYX Therapeutics touts study results for biodegradable oral adhesive patch
AFYX Therapeutics announced today that a study observed successful transmucosal delivery of a corticosteroid with its Rivelin patch. The Rivelin clobetasol patch (Rivelin-CLO) is a novel adhesive patch designed to deliver a therapeutic agent to wet tissue surfaces. The study, published in The European Journal of Oral Sciences, was the first to show the successful […]
Xeris Pharmaceuticals prices $27M offering
Xeris Pharmaceuticals (NSDQ:XERS) announced today that it priced a registered direct offering of common stock at $27 million. Chicago-based Xeris is offering nearly 6.6 million shares of common stock to funds managed by Deerfield Management Company, which are existing investors in the company, according to a news release. The offering is priced at $4.12 per share, […]
AVEO Oncology names new chief commercial officer
AVEO Oncology (NSDQ:AVEO) announced that it appointed Mike Ferraresso as its new chief commercial officer. Boston-based AVEO Oncology said in a news release that Feraresso will manage the company’s commercial strategy and operations, including the commercialization of Fotivda (tivozanib), a differentiated, oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). Fotivda is […]
Takeda to acquire T-cell engager therapy maker Maverick Therapeutics for $525M
Takeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million. Osaka, Japan-based Takeda exercised its option to acquire Maverick and its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages. Following the closing of the deal, Maverick employees will join […]
Neurelis closes $114M Series D for diazepam nasal spray
Neurelis announced today that it closed a $114 million Series D financing round to support its lead orphan drug product. San Diego-based Neurelis’ Valtoco (diazepam nasal spray) is a proprietary formulation incorporating the science of Intravail transmucosal absorption enhancement technology. The drug enables the noninvasive delivery of a range of drugs, while the company focuses […]
Cure Pharmaceutical launches antiviral, anti-seizure development programs
Drug delivery technology developer Cure Pharmaceutical (OTC:CURR) announced today that it launched two new clinical development programs. Oxnard, Calif.-based Cure’s first new launch is an antiviral clinical development program for loading a known active pharmaceutical ingredient (API) onto its Curefilm patented drug delivery platform that optimizes the absorption and metabolism of therapeutic devices, according to […]
